Bromocriptine

Bromocriptine is a semisynthetic ergoline, a chemical derivative of the natural ergot alkaloid ergocryptine that is produced by brominating the parent molecule. It behaves as a dopamine agonist, chiefly stimulating dopamine D2 receptors, and also interacts with serotonin and adrenergic receptors ^[1]. Scientists at the pharmaceutical company Sandoz discovered it in the 1960s; it was patented in 1968 and approved for medical use in 1975, with a rapid-release formulation later approved for a separate indication ^[1].

Its longest-standing uses stem from its ability to suppress the pituitary hormone prolactin. Bromocriptine treats hyperprolactinemia and prolactin-secreting pituitary tumors (prolactinomas), where it can lower prolactin levels and shrink tumor size, helping to restore fertility and normal hormone function; for prolactinomas the related agonist cabergoline is often preferred because it tends to be more effective and better tolerated ^[2]. Because dopamine drives the brain's movement circuits, bromocriptine is also used in Parkinson disease, and its ability to lower prolactin and growth hormone makes it useful in acromegaly ^[1].

A quick-release formulation has been approved as an add-on treatment for type 2 diabetes. Taken in the morning, it is thought to act on central dopamine signaling to improve the body's handling of glucose, and reviews describe it as a generally safe option with a favorable long-term profile ^[1]. As with other dopamine agonists, treatment can occasionally trigger impulse-control problems such as compulsive gambling or shopping, an effect studied more often with the higher doses used in Parkinson disease ^[3].

Bromocriptine is a prescription medicine sold under brand names such as Parlodel and, for diabetes, Cycloset, and is available in oral tablet and capsule forms. Its broad activity across dopaminergic and other monoamine receptors accounts for both its therapeutic effects and its characteristic side effects such as nausea and low blood pressure ^[1][4].

Bromocriptine is prescription only. Common effects are nausea, dizziness, low blood pressure on standing, headache, nasal stuffiness and fatigue, and starting low at bedtime with food helps limit the nausea. As an ergot drug, long term high doses carry a small risk of fibrosis of the heart valves or the lungs. It can cause psychiatric effects and impulse control disorders such as compulsive gambling. It is avoided in uncontrolled high blood pressure and certain pregnancy related blood pressure conditions, and it interacts with strong CYP3A4 inhibitors, other dopamine drugs and dopamine blocking antipsychotics.

Bromocriptine, a dopamine agonist, has its therapeutic effects opposed by dopamine receptor antagonists such as metoclopramide. Metoclopramide does not fully antagonize bromocriptine's prolactin-suppressing effect, suggesting bromocriptine retains some efficacy despite dopamine antagonism ^[7]. This is a pharmacodynamic interaction; the antagonist blocks the dopamine receptor activation that bromocriptine requires. The direction is clear; dopamine antagonists reduce bromocriptine efficacy, not the reverse. Bromocriptine is a dopamine agonist used in Parkinson's disease ^[8]. Limited data exist on bromocriptine interaction with CYP3A4 inhibitors or other medications that alter its metabolism.

Checking a whole stack? Run it through interactions + stacks.

Bromocriptine was developed by Sandoz in the late 1960s as a semisynthetic derivative of ergot alkaloids and became one of the first clinically useful dopamine agonists. It entered medical use in the 1970s, initially to suppress excess prolactin and to shrink prolactin-secreting pituitary tumors, and was later applied to Parkinson disease and acromegaly. Decades after its introduction, a quick-release morning formulation was approved in the United States in 2009 under the name Cycloset for type 2 diabetes, an application built on the observation that central dopamine signaling influences glucose metabolism. Its long history has made it a reference compound against which newer, more selective dopamine agonists are often compared.

Bromocriptine holds a respected place in endocrinology as a pioneering dopamine agonist that reshaped the medical management of hyperprolactinemia and prolactinomas, sparing many patients from surgery. Its later reinvention as a diabetes therapy is a notable example of drug repurposing, and systematic reviews report modest but real reductions in HbA1c when it is added to other treatments. Clinicians appreciate its decades-long track record, while acknowledging that nausea, fatigue, and headache are common enough that some patients favor newer agonists such as cabergoline. Overall it is viewed as an effective, well-characterized medicine whose main limitations are tolerability rather than efficacy.